The Milan experience with adjuvant chemotherapy in premenopausal breast cancer.
暂无分享,去创建一个
[1] Stephen E. Jones,et al. Adjuvant Therapy of Cancer , 1990 .
[2] G. Bonadonna,et al. The contribution of medicine to the primary treatment of breast cancer. , 1988, Cancer research.
[3] H. Mouridsen,et al. Evidence of a castration-mediated effect of adjuvant cytotoxic chemotherapy in premenopausal breast cancer. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] I. Henderson,et al. Adjuvant systemic therapy for early breast cancer. , 1987, Current Problems in Cancer.
[5] J H Goldie,et al. The genetic origin of drug resistance in neoplasms: implications for systemic therapy. , 1984, Cancer research.
[6] G. Bonadonna,et al. The CMF program for operable breast cancer with positive axillary nodes: Updated analysis on the disease‐free interval, site of relapse and drug tolerance , 1977, Cancer.
[7] M. Pike,et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. , 1977, British Journal of Cancer.
[8] G. Bonadonna,et al. Combination chemotherapy as an adjuvant treatment in operable breast cancer. , 1976, The New England journal of medicine.
[9] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .
[10] M. Zelen,et al. A randomized trial of adjuvant combination chemotherapy with or without prednisone in premenopausal breast cancer patients with metastases in one to three axillary lymph nodes. , 1985, Cancer research.
[11] G. Bonadonna,et al. Adjuvant CMF in breast cancer: comparative 5-year results of 12 versus 6 cycles. , 1983, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.